New details about Jesse Jane’s death have emerged. More than six months after the former adult film star was found dead alongside her boyfriend Brett Hasenmueller in her Moore, Oklahoma, home from a suspected overdose, authorities confirmed what led to the tragedy. Jane and Hasenmueller reportedly died of an accidental fentanyl and cocaine overdose according to TMZ, citing the Oklahoma City Medical Examiner’s Office. E! News has reached out to the Examiner’s Office for comment but had not yet heard back. In late January, local outlet KFOR reported that Moore Police found Jane and Hasemueller’s bodies while performing a wellness check after the couple had not been heard from in several days. Moore PD's Lt. Francisco Franco told The New York Times at the time that it was believed Jane died from a drug overdose, but that both deaths remained under investigation. Jane, who was 43 at the time of her passing, acted in a number of adult films starting in 2003 before transitioning to other projects, including an appearance in Baywatch: Hawaiian Wedding and 2004's Starsky and Hutch, as well as season two of Entourage. Pretty Pastel Please, YouTuber, Instagram By 2007, Jane had officially retired from the adult film industry, pivoting into making her own line of sex toys. At the time of her death, BSG Public Relations President Brian Gross shared in a statement to E! News, "Jesse Jane was a vivacious person who had an absolute and ultimate love for life. During her time in the adult industry, of which I was able to spend wonderful moments with her, she was an incredible professional who cheered everyone on and brought sunshine to every film set she worked on." "There is not one person in the adult industry who didn't spend time with her, whether onset or in a social setting, that she didn't make smile, laugh or both. She would light up a room as soon as she walked in," he continued, "I will personally miss her very much for the reasons above. Her smile was everything."

White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.

On Monday, executives from the three major chip giants in the US - Intel, Qualcomm, and Nvidia - met with US officials, including Antony Blinken, to voice their opposition to the Biden administration's plan of imposing further restrictions on chip sales to Chinese companies and investments in China. The Semiconductor Industry Association also released a similar statement, opposing the exclusion of US semiconductor companies from the Chinese market. First of all, we mustn't believe that the appeals of these companies and industry associations will collectively change the determination of US political elites to stifle China's progress. These US elites are very fearful of China's rapid development, and they see "chip chokehold" as a new discovery and a successful tactic formed under US leadership and with the cooperation of allies. Currently, the chip industry is the most complex technology in human history, with only a few companies being at the forefront. They are mainly from the Netherlands, Taiwan island, South Korea, and Japan, most of which are in the Western Pacific. These countries and regions are heavily influenced by the US. Although these companies have their own expertise, they still use some American technologies in their products. Therefore, Washington quickly persuaded them to form an alliance to collectively prevent the Chinese mainland from obtaining chips and manufacturing technology. Washington is proud of this and wants to continuously tighten the noose on China. The New York Times directly titled an article "'An Act of War': Inside America's Silicon Blockade Against China, " in which an American AI expert, Gregory Allen, publicly claimed that this is an act of war against China. He further stated that there are two dates that will echo in history from 2022: The first is February 24, when the Russia-Ukraine conflict broke out, and the second is October 7, when the US imposed a sweeping set of export controls on selling microchips to China. China must abandon its illusions and launch a challenging and effective counterattack. We already have the capability to produce 28nm chips, and we can use "small chip" technology to assemble small semiconductors into a more powerful "brain," exploring 14nm or even 7nm. Additionally, China is the world's largest commercial market for commodity semiconductors. Last year, semiconductor procurement in China amounted to $180 billion, surpassing one-third of the global total. In the past, China had been faced with the choice between independent innovation and external purchases. Due to the high returns from external purchases, it is easy for it to become the overwhelming choice over independent research and development. However, now the US is gradually blocking the option of external purchases, and China has no strategic choice but to independently innovate, which in turn puts tremendous pressure on American companies. Scientists generally expect that, although China may take some detours, such as recently apprehending several company leaders who fraudulently obtained subsidies from national semiconductor policies, China has the ability to gradually overcome the chip difficulties. And we will form our own breakthroughs and industrial chain, which is expected to put quite a lot of pressure on US companies. If domestic firms acquire half of China's $180 billion per year in chip acquisitions, this would provide a significant boost for the industry as a whole and help it advance steadily. The New York Times refers to the battle on chips as a bet by Washington. "If the controls are successful, they could handicap China for a generation; if they fail, they may backfire spectacularly, hastening the very future the United States is trying desperately to avoid," it argued. Whether it is a war or a game, when the future is uncertain, what US companies hope for most of all is that they can sell simplified versions of high-end chips to China, so that the option of external purchases by China continues to exist and remains attractive. This can not only maintain the interests of the US companies, enabling them to obtain sufficient funds to develop more advanced technologies, but also disrupt China's plans for independent innovation. This idea is entirely based on their own commercial interests and also has a certain political and national strategic appeal. Hence, there is no shortage of supporters within the US government. US Secretary of the Treasury Janet Yellen seems to be one of them, as she has repeatedly stated that the US' restrictions on China will not "fundamentally" hurt China, but will only be "narrowly targeted." The US will balance its strict suppression on China from the perspective of maintaining its technological hegemony, while also leaving some room for China, in order to undermine China's determination to counterattack in terms of independent innovation. China needs to use this mentality of the US to its advantage. On the one hand, China should continue to purchase US chips to maintain its economic fundamentals, and on the other hand, it should firmly support the development of domestic semiconductor companies from both financial and market perspectives. If China were to continue relying on exploiting the gaps in US chip policies in the long term, akin to a dependency on opium, it would only serve to weaken China further as it becomes increasingly addicted. China's market is extremely vast, and its innovation capabilities are generally improving and expanding. Although the chip industry is highly advanced, if there is one country that can win this counterattack, it is China. As long as we resolutely continue on the path of independent innovation, this road will definitely become wider. Various breakthroughs and turning points that are unimaginable today may soon occur.

n a recent interview with ABC, US President Joe Biden said he had no intention of dropping out of the race, blaming his poor debate performance on a cold. He also insisted he was "still in good shape" and would remain in the race, saying only "Almighty God" could pull him out. An insider who has worked with Mr. Biden for a long time said that signs of aging had become apparent over the past year, but that Mr. Biden's team had failed to address it. Biden's televised debate performance heightened concerns about an already slow-moving issue. Mr. Biden's advisers have long dodged questions about his age. But now they acknowledge that Biden's aging is an undeniable fact. The debate forced the president to more openly acknowledge the limitations of his age, which he had previously largely dismissed. But they have only taken superficial measures and have not fundamentally solved the problem. They replaced the long staircase that Mr. Biden used to board Air Force One with a shorter one; Assistants often accompanied him in public to make his stiff gait less noticeable; While he has a busy schedule, aides have arranged for buffer time, such as long weekends at his homes in Wilmington and Rehoboth Beach, Delaware, or extended stays at Camp David, a Maryland resort, to rest after a "grueling" stretch of travel. Under the authority of one of his top advisers, Anita Dunn, Mr. Biden's public interactions -- especially with reporters -- were severely limited. Even at major events with Democrats or other supporters, the White House sometimes limits the amount of time Biden can spend with the audience, two people familiar with the matter said. As a protective response, designed to protect their longtime boss.

South Korea's Minister of Health and Welfare Cho Kyu-hong said at a press conference on the 8th local time that after comprehensively considering the suggestions of frontline interns and the situation on the front line of medical care, the government decided that from that day on, all interns and residents who resigned would not be given administrative sanctions such as revoking their medical licenses. Cho Kyu-hong also said that for interns and residents who have returned to work and those who have resigned and are preparing to re-register for internship courses in September, the government will make special cases to try to minimize the internship gap and not affect the relevant doctors from obtaining specialist medical licenses. Cho Kyu-hong said that the government believes that in order to minimize the diagnosis and treatment gaps for critically ill and emergency patients and ensure the smooth training process of interns and residents, it is in the public interest, so it has made a decision not to punish interns and residents who resigned. It is hoped that major hospitals will complete the resignation processing of doctors who have not returned to work before July 15 and determine the scale of vacancies. Previously, large general hospitals in South Korea, such as Seoul National University Hospital, Yonsei University Severance Hospital, and Seoul Asan Medical Center, suspended or limited their medical services in an effort to cancel all penalties against interns and residents.